纤维化性结缔组织病相关间质性肺疾病进展的危险因素分析

doi:10.3877/cma.j.issn.1674-6902.2025.03.017

中华肺部疾病杂志(电子版) ›› 2025, Vol. 18 ›› Issue (03) : 434 -441. doi: 10.3877/cma.j.issn.1674-6902.2025.03.017

论著

纤维化性结缔组织病相关间质性肺疾病进展的危险因素分析

张丽丽¹^,², 韩志海³, 张春阳³, 陈韦³, 康奕欣⁴, 张燕³, 孟激光⁵, 丁毅伟³, 丁静³, 崔俊昌¹^,²^,^†(

)

^1. 100091 北京，解放军总医院第八医学中心呼吸与危重症医学部
^2. 100853 北京，解放军医学院
^3. 100048 北京，解放军总医院第六医学中心呼吸与危重症医学科
^4. 300071 天津，南开大学医学院
^5. 100142 北京，解放军总医院第四医学中心呼吸与危重症医学科

收稿日期:2024-11-26 出版日期:2025-06-25
通信作者: 崔俊昌
基金资助:
国家重点研发计划（2023YFC2507101）解放军总医院第六医学中心创新培育基金（CXPY202309）

Analysis of risk factors for progression and development of a predictive model in Fibrotic CTD-ILD

Lili Zhang¹^,², Zhihai Han³, Chunyang Zhang³, Wei Chen³, Yixin Kang⁴, Yan Zhang³, Jiguang Meng⁵, Yiwei Ding³, Jing Ding³, Junchang Cui¹^,²^,^†()

^1. Senior Department of Respiratory and Critical Care Medicine，the Eighth Medical Center，Chinese PLA General Hospital，Beijing 100091，China
^2. Chinese PLA Medical School，Beijing 100853，China
^3. Department of Respiratory and Critical Care Medicine，the Sixth Medical Center，Chinese PLA General Hospital，Beijing 100048，China
^4. School of Medicine，Nankai University，Tianjin 300071，China
^5. Department of Respiratory and Critical Care Medicine，the Fourth Medical Center，Chinese PLA General Hospital，Beijing 100142，China

Received:2024-11-26 Published:2025-06-25
Corresponding author: Junchang Cui

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

张丽丽, 韩志海, 张春阳, 陈韦, 康奕欣, 张燕, 孟激光, 丁毅伟, 丁静, 崔俊昌. 纤维化性结缔组织病相关间质性肺疾病进展的危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(03): 434-441.

Lili Zhang, Zhihai Han, Chunyang Zhang, Wei Chen, Yixin Kang, Yan Zhang, Jiguang Meng, Yiwei Ding, Jing Ding, Junchang Cui. Analysis of risk factors for progression and development of a predictive model in Fibrotic CTD-ILD[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(03): 434-441.

目的

分析纤维化性结缔组织病相关间质性肺疾病（connective tissue disease-associated interstitial lung disease，CTD-ILD）进展的危险因素并构建预测。

方法

收集2019 年1 月至2023 年12 月住院接受治疗的132 例纤维化性CTD-ILD 患者基线临床资料，根据随访中是否发生进展分为疾病稳定78 例为对照组，疾病进展54 例为观察组。采用LASSO 回归、随机森林、单因素Logistic 回归三种方法进行变量筛选，筛选出的共有变量纳入多因素逐步Logistic 回归进一步分析，寻找纤维化性CTD-ILD 进展的危险因素，基于多因素逐步回归构建预测并进行分析。

结果

多因素逐步Logistic 回归分析结果显示，有病毒感染史（OR=8.735，95% CI：2.754～27.711，P＜0.001）、DLCO%pred （OR=0.962，95% CI：0.930～0.995，P＜0.001）、HRCT 有蜂窝影（OR=7.685，95% CI：2.399 ～24.613，P＜0.001）、合并肺动脉高压（pulmonary hypertension，PH）（OR=19.812，95% CI：4.152～94.534，P＜0.001）与纤维化性CTD-ILD 的进展相关。基于上述因素构建列线图预测，在训练集的ROC 曲线AUC 为0.92，其对应的敏感度为0.81，特异度为0.89，95% CI：0.87～0.97，在测试集的ROC 曲线AUC 为0.95，其对应的敏感度为0.82，特异度为0.75，95% CI：0.88～1.00，提示预测具有很好的区分力。训练集及测试集所绘制的校准曲线与标准曲线均基本接近，提示模型有校准能力。决策曲线显示训练集及测试集在较大的阈值内均有临床净收益，有较好的临床实用性。

结论

病毒感染史、基线低水平DLCO%pred、合并PH 及HRCT 出现蜂窝影与纤维化性CTD-ILD 进展相关。

关键词: 结缔组织病, 间质性肺疾病, 肺纤维化, 进展性肺纤维化, 危险因素

Objective

To investigate the risk factors of he progression of fibrotic connective tissue disease-associated interstitial lung disease （CTD-ILD） and constructing predictive models.

Methods

The baseline clinical data of patients with fibrosing CTD-ILD who were hospitalized in the Department of Pulmonary and Critical Care Medicine of the Fourth，Sixth and Eighth Medical Centers of the PLA General Hospital from January，2019 to December，2023 were collected. The patients were divided into a stable group and a progressive group （PPF group） based on whether progression occurred during follow-up，The variables were preliminarily screened by four different methods including LASSO regression，random forest，gradient boosting machine，and one-way analysis of variance. The screened covariates were incorporated into multivariate stepwise Logistic regression for three analysis to identify the risk factors for the progression of fibrotic. Based on multivariate stepwise regression，a predictive model for the progression of CTD-ILD was constructed and evaluated.

Results

The multivariate stepwise regression results demonstrated that a history of novel coronavirus infection（OR=8.735，95% CI：2.754 ～27.711，P＜0.001），DLCO%pred （OR=0.962，95% CI：0.930 ～0.995，P＜0.001），DLCO%pred ≥60%（OR=0.07，P =0.016），honeycomb shadow on HRCT（OR=7.685，95% CI：2.399～24.613，P＜0.001），combined pulmonary hypertension （OR=19.812，95% CI：4.152 ～94.534，P＜0.001）were independently related to the progression of fibrotic CTD-ILD. The area under the ROC curve （AUC） of the predictive model constructed based on stepwise regression was 0.92 in the training set，and the corresponding sensitivity，specificity，and 95%CI were 0.81，0.89，and 0.87～0.97，respectively； the AUC of the predictive model was 0.95 in the test set，and the corresponding sensitivity，specificity，and 95%CI were 0.82，0. 75，and 0. 88 ～1. 00，respectively. These results indicated that the model had an excellent discrimination ability. The calibration curves plotted based on the training set and the test set were basically consistent with the standard curves，which suggested that the model had a favorable calibration ability. The decision curve analysis （DCA） revealed that the model had a higher clinical net benefit within a large threshold in both the training set and the test set，which indicated that the model had favorable clinical utility.

Conclusion

A history of novel coronavirus infection，low level of DLCO%pred at baseline，combined pulmonary hypertension，and honeycomb shadow on HRCT are closely related to the progression of pulmonary fibrosis in patients with fibrotic CTD-ILD. The model constructed based on the above factors can accurately predict the progression of progressive fibrotic CTD-ILD and has certain clinical utility and generalization potency.

Key words: Connective tissue disease, Interstitial lung disease, Pulmonary fibrosis, Progressive pulmonary fibrosis, Risk factors

表1 两组纤维化性CTD-ILD 患者临床资料比较［n（%），（）］

临床资料	对照组（n=78）	观察组（n=54）	χ²/t/Z 值	P 值
吸烟	24 (30.8)	25 (46.3)	3.296	0.069
mMRC			12.102	0.000
≥1 分	69 (88.46)	34 (62.96)
<1 分	9 (11.54)	20 (37.04)
病程(个月)	41.90±17.50	40.91±17.13	0.163	0.687
LYM(L⁻¹,×10⁹)	1.78±0.88	1.41±0.74	6.31	0.013
PLT(L⁻¹,×10⁹)	236.85±77.29	214.46±76.88	2.688	0.104
ALB(g·L⁻¹)	37.96±11.79	39.84±40.60	9.765	0.002
HRCT	16 (20.51)	36 (66.67)
PH	3 (3.85)	25 (46.3)	34.406	0.000
NLR/M(IQR)	2.86(1.71,3.91)	3.00(2.20, 6.28)	1.941	0.164
LHR/M(IQR)	1.33(1.06,1.89)	1.06(0.67,1.75)	4.563	0.033
CA19-9/[(U·ml⁻¹, M(IQR)]	11.80(7.93,22.12)	20.15(11.77,71.60)	11.107	0.000
CEA/[(ng·ml⁻¹, M(IQR)]	2.60(1.60, 4.54)	3.02(1.90, 4.86)	2.448	0.118
CA125/[(U·ml⁻¹, M(IQR)]	18.82(11.21,25.48)	21.26(10.12,45.02)	1.224	0.269
FVC%pred/M(IQR)	92.55(83.00,96.38)	87.25(83.12,90.48)	4.913	0.027
DLCO%pred/M(IQR)	80.90(69.57,87.77)	61.30(53.60,70.23)	28.929	<0.001

表1 两组纤维化性CTD-ILD 患者临床资料比较［n（%），（）］

临床资料	对照组（n=78）	观察组（n=54）	χ²/t/Z 值	P 值
吸烟	24 (30.8)	25 (46.3)	3.296	0.069
mMRC			12.102	0.000
≥1 分	69 (88.46)	34 (62.96)
<1 分	9 (11.54)	20 (37.04)
病程(个月)	41.90±17.50	40.91±17.13	0.163	0.687
LYM(L⁻¹,×10⁹)	1.78±0.88	1.41±0.74	6.31	0.013
PLT(L⁻¹,×10⁹)	236.85±77.29	214.46±76.88	2.688	0.104
ALB(g·L⁻¹)	37.96±11.79	39.84±40.60	9.765	0.002
HRCT	16 (20.51)	36 (66.67)
PH	3 (3.85)	25 (46.3)	34.406	0.000
NLR/M(IQR)	2.86(1.71,3.91)	3.00(2.20, 6.28)	1.941	0.164
LHR/M(IQR)	1.33(1.06,1.89)	1.06(0.67,1.75)	4.563	0.033
CA19-9/[(U·ml⁻¹, M(IQR)]	11.80(7.93,22.12)	20.15(11.77,71.60)	11.107	0.000
CEA/[(ng·ml⁻¹, M(IQR)]	2.60(1.60, 4.54)	3.02(1.90, 4.86)	2.448	0.118
CA125/[(U·ml⁻¹, M(IQR)]	18.82(11.21,25.48)	21.26(10.12,45.02)	1.224	0.269
FVC%pred/M(IQR)	92.55(83.00,96.38)	87.25(83.12,90.48)	4.913	0.027
DLCO%pred/M(IQR)	80.90(69.57,87.77)	61.30(53.60,70.23)	28.929	<0.001

表2 纤维化性CTD-ILD 进展的单因素Logistic 回归

变量/指标	β值	标准误	Z值	P值	OR	95%CI
mMRC 评分 ≥1 分	1.437	0.513	2.800	0.005	4.209	1.587~ 12.151
病毒感染史	1.959	0.456	4.297	0.001	7.091	2.978~ 17.951
白蛋白计数/ （g·L⁻¹）	-0.118	0.051	-2.304	0.021	0.889	0.800~ 0.979
淋巴细胞计数/ （L⁻¹, ×10⁹）	-0.586	0.267	-2.190	0.029	0.557	0.318~ 0.911
LHR	-0.525	0.280	-1.874	0.061	0.591	0.328~ 0.968
NLR	0.090	0.051	1.754	0.079	1.094	0.999~ 1.226
血小板计数/ （g·L⁻¹）	-0.004	0.003	-1.408	0.159	0.996	0.991~ 1.001
CA19-9/ （U·ml⁻¹）	0.004	0.002	1.796	0.073	1.004	1.000~ 1.010
CEA/ （ng·ml⁻¹）	0.002	0.002	0.863	0.388	1.002	0.998~ 1.009
CA125/ （U·ml⁻¹）	0.040	0.054	0.748	0.455	1.041	0.938~ 1.182
FVC%pred	-0.013	0.013	-0.990	0.322	0.987	0.962~ 1.012
DLCO% pred	-0.071	0.016	-4.327	0.001	0.931	0.899~ 0.960
HRCT 有蜂窝影	2.377	0.474	5.009	0.001	10.771	4.396~ 28.526
合并 PH	2.554	0.669	3.818	0.001	12.859	3.911~ 58.571

表2 纤维化性CTD-ILD 进展的单因素Logistic 回归

变量/指标	β值	标准误	Z值	P值	OR	95%CI
mMRC 评分 ≥1 分	1.437	0.513	2.800	0.005	4.209	1.587~ 12.151
病毒感染史	1.959	0.456	4.297	0.001	7.091	2.978~ 17.951
白蛋白计数/ （g·L⁻¹）	-0.118	0.051	-2.304	0.021	0.889	0.800~ 0.979
淋巴细胞计数/ （L⁻¹, ×10⁹）	-0.586	0.267	-2.190	0.029	0.557	0.318~ 0.911
LHR	-0.525	0.280	-1.874	0.061	0.591	0.328~ 0.968
NLR	0.090	0.051	1.754	0.079	1.094	0.999~ 1.226
血小板计数/ （g·L⁻¹）	-0.004	0.003	-1.408	0.159	0.996	0.991~ 1.001
CA19-9/ （U·ml⁻¹）	0.004	0.002	1.796	0.073	1.004	1.000~ 1.010
CEA/ （ng·ml⁻¹）	0.002	0.002	0.863	0.388	1.002	0.998~ 1.009
CA125/ （U·ml⁻¹）	0.040	0.054	0.748	0.455	1.041	0.938~ 1.182
FVC%pred	-0.013	0.013	-0.990	0.322	0.987	0.962~ 1.012
DLCO% pred	-0.071	0.016	-4.327	0.001	0.931	0.899~ 0.960
HRCT 有蜂窝影	2.377	0.474	5.009	0.001	10.771	4.396~ 28.526
合并 PH	2.554	0.669	3.818	0.001	12.859	3.911~ 58.571

表3 纤维化性CTD-ILD 患者进展的多因素逐步Logistic 回归分析

指标/因素/自变量	β值	SE值	Z值	OR	P值	95%CI
病毒感染史	2.167	0.589	3.680	8.735	0.001	2.754~27.711
HRCT 有蜂窝影	2.039	0.594	3.433	7.685	0.001	2.399~24.613
合并 PH	2.986	0.797	3.746	19.812	0.001	4.152~94.534
DLCO%pred	-0.039	0.017	-2.232	0.962	0.026	0.930~0.995

表3 纤维化性CTD-ILD 患者进展的多因素逐步Logistic 回归分析

指标/因素/自变量	β值	SE值	Z值	OR	P值	95%CI
病毒感染史	2.167	0.589	3.680	8.735	0.001	2.754~27.711
HRCT 有蜂窝影	2.039	0.594	3.433	7.685	0.001	2.399~24.613
合并 PH	2.986	0.797	3.746	19.812	0.001	4.152~94.534
DLCO%pred	-0.039	0.017	-2.232	0.962	0.026	0.930~0.995

图1 纤维化性CTD-ILD 进展的Nomogram 预测图

图2 多因素联合应用预测纤维化性CTD-ILD 进展的决策曲线。图A 为训练集决策曲线；图B 为测试集决策曲线

1	岳欢欢，黎联. KL-6 和Th1/Th2 细胞因子在结缔组织病相关性间质性肺炎中的表达及临床意义［J/CD］. 中华肺部疾病杂志（电子版），2020，13（1）：18-22.
2	Maher TM. Interstitial Lung Disease：a review［J］. JAMA，2024，331（19）：1655-1665.
3	Spagnolo P，Distler O，Ryerson CJ，et al. Mechanisms of progressive fibrosis in connective tissue disease （CTD）-associated interstitial lung diseases （ILDs）［J］. Ann Rheum Dis，2021，80（2）：143-150.
4	Lee JK，Ahn Y，Noh HN，et al. Clinical effect of progressive pulmonary fibrosis on patients with connective tissue diseaseassociated interstitial lung disease：a single center retrospective cohort study［J］. Clin Exp Med，2023，23（8）：4797-4807.
5	Wang Z，Zhang Z，Zhu L，et al. Identification of risk factors for acute exacerbation of idiopathic pulmonary fibrosis based on baseline high-resolution computed tomography：a prospective observational study［J］. BMC Pulm Med，2024，24（1）：352.
6	Hoyer N，Prior TS，Bendstrup E，et al. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis［J］. Respir Res，2019，20（1）：103.
7	George PM，Spagnolo P，Kreuter M，et al. Progressive fibrosing interstitial lung disease：clinical uncertainties，consensus recommendations，and research priorities［J］. Lancet Respir Med，2020，8（9）：925-934.
8	Huang H，Wang Q，Xu Z.Advances in the identification and management of progressive pulmonary fibrosis：perspective from Chinese experts［J］. Ther Adv Respir Dis，2024，18：17534666241288417.
9	Raghu G，Remy-Jardin M，Richeldi L，et al. Idiopathic pulmonary fibrosis （an Update） and progressive pulmonary fibrosis in adults：an official ATS/ERS/JRS/ALAT clinical practice guideline［J］. Am J Respir Crit Care Med，2022，205（9）：e18-e47.
10	Humbert M，Kovacs G，Hoeper MM，et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension［J］. Eur Heart J，2022，43（38）：3618-3731.
11	Jang JH，Choe EJ，Jung SY，et al. A study on the prevalence and prognosis of progressive pulmonary fibrosis：a retrospective observational study［J］. Medicine （Baltimore），2024，103（20）：e38226.
12	Wijsenbeek M，Swigris JJ，Inoue Y，et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis［J］. Eur Respir J，2024，63（2）：2300752.
13	Shao T，Shi X，Yang S，et al. Interstitial lung disease in connective tissue disease：a common lesion with heterogeneous mechanisms and treatment considerations［J］. Front Immunol，2021，12：684699.
14	Mara G，Nini G，Cotoraci C. Impact of pulmonary comorbidities on COVID-19：Acute and long-term evaluations［J］. J Clin Med，2025，14（5）：1446.
15	George PM，Wells AU，Jenkins RG. Pulmonary fibrosis and COVID-19：The potential role for antifibrotic therapy［J］. Lancet Respir Med，2020，8（8）：807-815.
16	Kudo R，Kawaguchi T，Kimura M，et al. Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema：an autopsy report［J］. Heliyon，2023，9（11）：e22221.
17	Fan JJ，Gu JM，Xiao SY，et al. Risk factors for progression of pulmonary fibrosis：a single-centered，retrospective study［J］. Front Med （Lausanne），2024，11：1335758.
18	Paterniti MO，Bi Y，Rekic D，et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis［J］. Ann Am Thorac Soc，2017，14（9）：1395-1402.
19	Oldham JM，Lee CT，Wu Z，et al. Lung function trajectory in progressive fibrosing interstitial lung disease［J］. Eur Respir J，2022，59（6）：2101396.
20	Chung JH，Montner SM，Thirkateh P，et al. Computed tomography findings suggestive of connective tissue disease in the setting of usual interstitial pneumonia［J］. J Comput Assist Tomogr，2021，45（5）：776-781.
21	Leavy OC，Kawano-Dourado L，Stewart ID，et al. Rheumatoid arthritis and idiopathic pulmonary fibrosis：a bidirectional Mendelian randomisation study［J］. Thorax，2024，79（6）：538-544.
22	Yoo H，Hino T，Hwang J，et al. Connective tissue disease-related interstitial lung disease （CTD-ILD） and interstitial lung abnormality（ ILA ）：Evolving concept of CT findings，pathology and management［J］. Eur J Radiol Open，2022，9：100419.
23	Adegunsoye A，Oldham JM，Bellam SK，et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases［J］. Ann Am Thorac Soc，2019，16（5）：580-588.
24	Shah RM，Kolansky AM，Kligerman S. Thin-section CT in the categorization and management of pulmonary fibrosis including recently defined progressive pulmonary fibrosis ［J］. Radiol Cardiothorac Imaging，2024，6（1）：e230135.
25	Zhao H，Wang L，Yan Y，et al. Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis ［J］. Front Immunol，2023，14：1197752.
26	Ruffenach G，Hong J，Vaillancourt M，et al. Pulmonary hypertension secondary to pulmonary fibrosis：clinical data，histopathology and molecular insights［J］. Respir Res，2020，21（1）：303.
27	Zubairi A，Ahmad H，Hassan M，et al. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis：an experience from a tertiary care center in Pakistan［J］. Clin Respir J，2018，12（3）：1191-1196.
28	Yagi M，Taniguchi H，Kondoh Y，et al. CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis ［J］.Respirology，2017，22（7）：1393-1399.
29	Zouk AN，Gulati S，Xing D，et al. Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis：a cohort study［J］. PLoS One，2020，15（2）：e0229173.
30	Zhao K，Zhang J，Kong Q，et al. Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease［J］. Arthritis Res Ther，2025，27（1）：32.

[1]	朱晓璐, 孙希希, 柴佳园, 董泽洋, 赵梦瑶, 黄斌. 超声引导下医用无水乙醇硬化治疗卵巢子宫内膜异位囊肿疗效的影响因素分析[J/OL]. 中华医学超声杂志（电子版）, 2025, 22(03): 215-223.
[2]	肖志满, 张泽锋, 庄锡其, 肖青福. 关节镜术后下肢深静脉血栓早期及远期发生的对比[J/OL]. 中华关节外科杂志(电子版), 2025, 19(02): 253-256.
[3]	谌莉, 冉永红, 傅仕艳, 李文润, 冉新泽, 郝玉徽. 放射性肺纤维化细胞和分子机制的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(03): 265-270.
[4]	李培真, 刘海亮, 李大伟, 贾昊, 张泽瑾, 刘力维, 申传安. 重度烧伤患者发生早期急性肾损伤危险因素分析及预测模型建立[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(03): 199-205.
[5]	朱宗恒, 张志火. 甲状腺乳头状癌对侧中央区淋巴结转移的危险因素分析及预测模型构建[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 337-340.
[6]	钱小梅, 罗洪, 李智慧, 周代君, 李东. 76例乙型肝炎肝硬化并发原发性肝癌的高危因素Logistic分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 251-253.
[7]	吉林霞, 范小春, 梁琴. 胃癌常见术后并发症类型及危险因素研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 220-223.
[8]	杨培容, 潘刚, 周春霞. 胰腺癌术后胰瘘的危险因素及治疗进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 228-230.
[9]	华小玲, 高梦昕, 陈媛, 蔡超, 刘永达, 孙红玲. 良性输尿管狭窄修复重建术研究进展及再手术现状[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 377-383.
[10]	范高祥, 邓利文, 宋伟, 赵渝, 王学虎. 复发性腹股沟疝再次手术出血相关因素及临床处理策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2025, 19(02): 160-166.
[11]	周艳, 周泽阳, 程欣萌, 何月娥, 李祥勇, 吴勇. 结直肠癌患者早期造口并发症预测模型的构建与验证[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 242-250.
[12]	宋然, 郑雅各. 仑伐替尼联合肝动脉插管化疗栓塞术治疗不可切除晚期肝癌的疗效及生存率影响因素分析[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(02): 120-124.
[13]	王双兴, 吴永杰, 孟兵, 张宏涛, 魏丹, 张辉, 刁美. 非限制性室间隔缺损婴儿术后延迟恢复危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2025, 19(03): 188-193.
[14]	马丽, 刘文华, 刘丹, 王晓彤, 康微婉, 张毅, 王雪娇. 终末期肾脏病腹膜透析相关性腹膜炎病原菌及危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2025, 19(03): 194-198.
[15]	李雯婷, 高聪, 廖晓凌. 卒中后认知障碍的危险因素及临床预测模型的研究进展[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(02): 81-86.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of risk factors for progression and development of a predictive model in Fibrotic CTD-ILD

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of risk factors for progression and development of a predictive model in Fibrotic CTD-ILD